Kenya Atherosclerosis Therapeutics Market Analysis

Kenya Atherosclerosis Therapeutics Market Executive Summary

Kenya Atherosclerosis Therapeutics Market was valued at $2 Mn in 2022 and is estimated to reach $3 Mn in 2030, exhibiting a CAGR of 6.8% during the forecast period.

Atherosclerosis causes plaque, a viscous material made up of calcium, fat, cholesterol, and other substances, to build up inside the walls of arteries. This accumulation increases the chance of major illnesses, including strokes and heart attacks, which can narrow or obstruct blood vessels. Numerous variables, such as high blood pressure, high cholesterol, diabetes, obesity, smoking, a family history of heart disease, a sedentary lifestyle, and an unhealthy diet, can cause atherosclerosis. Numerous drugs, including statins, aspirin, and beta-blockers, have shown potential for slowing or stopping the development of atherosclerosis.

Kenya has high rates of risk factors for atherosclerosis; the country's population is prone to dyslipidaemia (abnormal cholesterol levels), diabetes, and hypertension, which increases the risk of atherosclerosis. Based on their lipid profile, about 30% of the population is categorized as having a moderate or medium atherogenic risk. Autopsy investigations in Kenya have revealed a noteworthy incidence of atherosclerotic lesions, with more than 25% of the participants displaying these vascular anomalies.

Verquvo, also known as inclisiran, has received approval from the US Food and Drug Administration (FDA) to reduce cholesterol in adults with familial hypercholesterolemia. The potential for this medication to be sold in Kenya is contingent upon both market and regulatory concerns. Late-stage clinical studies investigating innovative treatments, such as PCSK9 inhibitors and CETP inhibitors, that target different aspects of atherosclerosis are showing exciting success. Once these innovations are approved by regulators and prove successful in clinical trials, they may find their way into the Kenyan market. These advancements represent a changing field in the treatment of atherosclerosis and highlight the potential for novel treatments to improve cardiovascular health in Kenya.

Market Dynamics

Market Growth Drivers

Ageing population: Kenya's aging population, currently comprising 4–6% of those aged 60 and above, is anticipated to more than double to 10.3% by 2050, driving a significant demographic shift. This rise in the elderly population underscores the increasing risk of atherosclerosis due to age-related factors. With the demand for effective treatments on the rise, the growing aging demographic presents a substantial opportunity for the expansion of the atherosclerosis drug treatment market in Kenya.

Improved Diagnosis and Awareness: Increased access to diagnostic tools such as angiography and ultrasonography, supported by public-private funding and government initiatives, is promoting early detection and treatment initiation in Kenya. Greater investments in healthcare infrastructure and impactful public awareness campaigns are driving the growth of the atherosclerosis drug treatment market. The presence of advanced diagnostic technologies aids early detection, while heightened public awareness fosters demand for both preventive measures and treatments, fostering market expansion.

Advancements in Drug Development: In response to the increasing number of patients and diverse requirements, pharmaceutical companies are anticipated to intensify their ongoing endeavours in creating innovative atherosclerosis drugs, customized to different pathways and patient needs. This concerted effort is poised to expedite the expansion of the market in Kenya.

Market Restraints

High cost of drugs: The high cost of original pharmaceuticals is a major barrier to the treatment of atherosclerosis in Kenya, especially for people living in remote regions and those with minimal financial resources. Branded drugs are extremely expensive. This functions as a market constraint, impeding these demographic groups' access to necessary atherosclerosis treatments.

Lack of Awareness and Education: Lack of knowledge about atherosclerosis, its risk factors, and the treatments that are available might cause a delay in diagnosis and prevent prompt medical action. The stigma attached to long-term conditions like atherosclerosis can prevent people from getting the care they need and adhering to treatment regimens. The quality of care can also be impacted by medical professionals' lack of knowledge and experience in treating non-communicable diseases like atherosclerosis. The market for atherosclerosis treatment drugs in Kenya is severely constrained by this lack of knowledge and education, which also leads to difficulties in providing appropriate therapies, delayed diagnosis, and cultural barriers to seeking medical attention. All of these factors eventually impede market growth.

Compliance and Adherence Issues: The prolonged use of drugs in atherosclerosis treatment poses challenges such as adverse effects, forgetfulness, and low motivation for some patients. Managing numerous prescriptions for different medical conditions makes adherence problems worse, which could limit the commercial potential of atherosclerosis treatment options because of difficulties with patient compliance.

Healthcare Policies and Regulatory Landscape

In Kenya, the Ministry of Health (MOH) and the Pharmacy and Poisons Board (PPB) are principally in charge of healthcare policy and regulatory control with regard to therapeutic medications. The Ministry of Health is in charge of developing and carrying out healthcare policies and making sure that medical services, including prescription drugs, are available, affordable, and of high quality. Under the MOH, the Pharmacy and Poisons Board is responsible for regulating and supervising the safety, quality control, licensing, and registration of pharmaceutical items. Through cooperation amongst regulatory agencies, a strong framework governing the creation, authorization, and distribution of treatment medications in Kenya is established, guaranteeing adherence to safety and efficacy requirements to protect the public's health.

Competitive Landscape

Key Players

• Pfizer
• Novartis
• AstraZeneca
• Sanofi
• Bayer
• Abbott
• Eli Lilly
• GlaxoSmithKline
• Teva Pharmaceutical
• Roche